Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors
暂无分享,去创建一个
J. Wichard | N. Vermeulen | A. T. Laak | M. van Dijk | D. Geerke | A. ter Laak | M. Dijk | Luigi Capoferri
[1] Martin Almlöf,et al. Free energy calculations and ligand binding. , 2003, Advances in protein chemistry.
[2] R. W. Hockney,et al. Time integration in particle models , 1987 .
[3] K. J. Ryan. Conversion of androstenedione to estrone by placental microsomes. , 1958, Biochimica et biophysica acta.
[4] Luigi Capoferri,et al. Improving the iterative Linear Interaction Energy approach using automated recognition of configurational transitions , 2016, Journal of Molecular Modeling.
[5] A. Bhatnagar,et al. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. , 1996, Acta oncologica.
[6] Chris Oostenbrink,et al. Computational Prediction of Binding Affinity for CYP1A2-Ligand Complexes Using Empirical Free Energy Calculations , 2010, Drug Metabolism and Disposition.
[7] Vasanthanathan Poongavanam,et al. A comparative study of binding affinities for 6,7-dimethoxy-4-pyrrolidylquinazolines as phosphodiesterase 10A inhibitors using the linear interaction energy method. , 2015, Journal of molecular graphics & modelling.
[8] P. Cole,et al. Mechanism and inhibition of cytochrome P-450 aromatase. , 1990, Journal of medicinal chemistry.
[9] Chris Oostenbrink,et al. Improved ligand-protein binding affinity predictions using multiple binding modes. , 2010, Biophysical journal.
[10] David Baker,et al. PROTEINS: Structure, Function, and Bioinformatics 58:893–904 (2005) A “Solvated Rotamer ” Approach to Modeling Water- Mediated Hydrogen Bonds at Protein–Protein Interfaces , 2022 .
[11] A. Brodie. Aromatase inhibitors in breast cancer , 2002, Trends in Endocrinology & Metabolism.
[12] Pramod C. Nair,et al. An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. , 2011, Journal of chemical theory and computation.
[13] Chartchalerm Isarankura-Na-Ayudhya,et al. Molecular Docking of Aromatase Inhibitors , 2011, Molecules.
[14] Chris Oostenbrink,et al. CYP 2D6 Binding Affinity Predictions Using Multiple Ligand and Protein Conformations , 2013, International journal of molecular sciences.
[15] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[16] R. Santen,et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer , 1995, Cancer.
[17] Nico P E Vermeulen,et al. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. , 2004, Journal of medicinal chemistry.
[18] Sebastian Schmidt,et al. Hands-off Linear Interaction Energy Approach to Binding Mode and Affinity Estimation of Estrogens , 2013, J. Chem. Inf. Model..
[19] Daan P. Geerke,et al. Towards Automated Binding Affinity Prediction Using an Iterative Linear Interaction Energy Approach , 2014, International journal of molecular sciences.
[20] Berk Hess,et al. Improving efficiency of large time‐scale molecular dynamics simulations of hydrogen‐rich systems , 1999, Journal of computational chemistry.
[21] J. Sridhar,et al. Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies , 2012, Molecules.
[22] Ming Yan,et al. Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay , 2014, Acta Pharmacologica Sinica.
[23] Shagufta,et al. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. , 2015, European journal of medicinal chemistry.
[24] Carsten Kutzner,et al. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.
[25] Chris Oostenbrink,et al. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450 , 2008 .
[26] G. McGaughey,et al. pi-Stacking interactions. Alive and well in proteins. , 1998, The Journal of biological chemistry.
[27] A. Cavalli,et al. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. , 2001, Journal of medicinal chemistry.
[28] W. Boon,et al. Aromatase--a brief overview. , 2002, Annual review of physiology.
[29] R. Brueggemeier,et al. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[30] Takako Sakamoto,et al. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. , 2010, The Journal of nutritional biochemistry.
[31] M. Dowsett,et al. ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[32] Andreas P. Eichenberger,et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7 , 2011, European Biophysics Journal.
[33] F. Guengerich,et al. Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.
[34] H. Berendsen,et al. Interaction Models for Water in Relation to Protein Hydration , 1981 .
[35] C. Laughton,et al. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. , 1996, Cancer research.
[36] Shiuan Chen,et al. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. , 2006, Cancer research.
[37] Sean Ekins,et al. Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.
[38] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[39] Thomas Stützle,et al. An ant colony optimization approach to flexible protein–ligand docking , 2007, Swarm Intelligence.
[40] Daan P. Geerke,et al. Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation , 2015, PloS one.
[41] R. Elledge,et al. Oestrogen receptors and breast cancer , 1997, BMJ.
[42] Chris Oostenbrink,et al. Are Automated Molecular Dynamics Simulations and Binding Free Energy Calculations Realistic Tools in Lead Optimization? An Evaluation of the Linear Interaction Energy (LIE) Method , 2006, J. Chem. Inf. Model..
[43] V. Njar,et al. Aromatase inhibitors and their application in breast cancer treatment☆ , 2000, Steroids.
[44] A. Cavalli,et al. Nonsteroidal aromatase inhibitors: Recent advances , 2002, Medicinal research reviews.
[45] Jur P. van den Berg,et al. A method to obtain a near‐minimal‐volume molecular simulation of a macromolecule, using periodic boundary conditions and rotational constraints , 2004, J. Comput. Chem..
[46] C. Osborne,et al. Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.
[47] J. Aqvist,et al. A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.
[48] J. Åqvist,et al. Ligand binding affinities from MD simulations. , 2002, Accounts of chemical research.
[49] Paulo Augusto Netz,et al. Linear interaction energy (LIE) method in lead discovery and optimization. , 2008, Current drug targets.
[50] Emilio Gallicchio,et al. Linear Interaction Energy (LIE) Models for Ligand Binding in Implicit Solvent: Theory and Application to the Binding of NNRTIs to HIV-1 Reverse Transcriptase. , 2007, Journal of chemical theory and computation.
[51] R. Santen,et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. , 1982, Annals of internal medicine.
[52] S. P. Lloyd,et al. Least squares quantization in PCM , 1982, IEEE Trans. Inf. Theory.
[53] Jozef Hritz,et al. Efficient free energy calculations for compounds with multiple stable conformations separated by high energy barriers. , 2009, The journal of physical chemistry. B.
[54] A. Eisen,et al. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. , 2008, Cancer treatment reviews.
[55] R. Santen,et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. , 1978, The Journal of clinical endocrinology and metabolism.
[56] E. J. Tavares da Silva,et al. Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation. , 2005, Journal of medicinal chemistry.
[57] David L Mobley,et al. Alchemical free energy methods for drug discovery: progress and challenges. , 2011, Current opinion in structural biology.
[58] Yongjun Wang,et al. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction , 2008, J. Comput. Aided Mol. Des..
[59] D. Flockhart,et al. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro , 2009, Cancer Chemotherapy and Pharmacology.
[60] J. Jackson,et al. Safety issues surrounding the use of aromatase inhibitors in breast cancer , 2003, Expert opinion on drug safety.
[61] Christine M. Bathelt,et al. Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9 , 2013, Journal of the American Chemical Society.
[62] Wilfred F. van Gunsteren,et al. A generalized reaction field method for molecular dynamics simulations , 1995 .
[63] N. Teixeira,et al. Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors , 2008, Steroids.
[64] C. Nantasenamat,et al. Probing the origins of aromatase inhibitory activity of disubstituted coumarins via QSAR and molecular docking , 2014, EXCLI Journal : Experimental and Clinical Sciences.
[65] W. Pangborn,et al. Structural basis for androgen specificity and oestrogen synthesis in human aromatase , 2009, Nature.
[66] D. A. Dougherty,et al. Cation-pi interactions in structural biology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[67] Thompson Ea,et al. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. , 1974 .
[68] Williams E. Miranda,et al. Improving the LIE Method for Binding Free Energy Calculations of Protein-Ligand Complexes , 2015, J. Chem. Inf. Model..
[69] C. Osborne,et al. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. , 1999, Endocrine-related cancer.
[70] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[71] TSJERK A. WASSENAAR,et al. The effect of box shape on the dynamic properties of proteins simulated under periodic boundary conditions , 2006, J. Comput. Chem..
[72] J. Kellis,et al. Purification and characterization of human placental aromatase cytochrome P-450. , 1987, The Journal of biological chemistry.
[73] Eric Westhof,et al. Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[74] Angelo Carotti,et al. Three‐dimensional model of the human aromatase enzyme and density functional parameterization of the iron‐containing protoporphyrin IX for a molecular dynamics study of heme‐cysteinato cytochromes , 2006, Proteins.
[75] U. Dwivedi,et al. Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer , 2015, Journal of biomolecular structure & dynamics.
[76] R. Brueggemeier,et al. Aromatase inhibitors in the treatment of breast cancer. , 2005, Endocrine reviews.
[77] G. McLachlan,et al. The EM Algorithm and Extensions: Second Edition , 2008 .
[78] H. Adlercreutz,et al. Aromatase inhibitor development for treatment of breast cancer , 2004, Breast Cancer Research and Treatment.
[79] E. Baker,et al. Hydrogen bonding in globular proteins. , 1984, Progress in biophysics and molecular biology.
[80] Michael R. Shirts,et al. Extremely precise free energy calculations of amino acid side chain analogs: Comparison of common molecular mechanics force fields for proteins , 2003 .
[81] W. L. Jorgensen,et al. AN EXTENDED LINEAR RESPONSE METHOD FOR DETERMINING FREE ENERGIES OF HYDRATION , 1995 .
[82] Johan Åqvist,et al. Ligand binding affinity prediction by linear interaction energy methods , 1998, J. Comput. Aided Mol. Des..
[83] Udayan Dutta,et al. Aromatase inhibitors: past, present and future in breast cancer therapy , 2008, Medical oncology.
[84] R. Galeazzi,et al. Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study , 2012, Journal of Molecular Modeling.
[85] Yate-Ching Yuan,et al. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. , 2007, Molecular endocrinology.
[86] W. Pangborn,et al. X-ray structure of human aromatase reveals an androgen-specific active site , 2010, The Journal of Steroid Biochemistry and Molecular Biology.
[87] P. Graves,et al. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. , 1979, Endocrinology.
[88] Andreas Bender,et al. Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..
[89] D. Sundar,et al. Insight into the Enzyme-Inhibitor Interactions of the First Experimentally Determined Human Aromatase , 2011, Journal of biomolecular structure & dynamics.
[90] D. Covey,et al. Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione. , 1989, Journal of medicinal chemistry.
[91] D. Tripathy,et al. Aromatase inhibitors: rationale and use in breast cancer. , 2005, Annual review of medicine.
[92] B Testa,et al. In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.
[93] J. Thornton,et al. Ion-pairs in proteins. , 1983, Journal of molecular biology.
[94] C. Watson,et al. Regulation of aromatase activity within the breast , 1997, The Journal of Steroid Biochemistry and Molecular Biology.
[95] Gerhard Wolber,et al. Molecular dynamics simulation and linear interaction energy study of d-Glu-based inhibitors of the MurD ligase , 2013, Journal of Computer-Aided Molecular Design.
[96] Giulio Rastelli,et al. Advances and applications of binding affinity prediction methods in drug discovery. , 2012, Biotechnology advances.
[97] Alexandre M J J Bonvin,et al. A Flexible, Grid-Enabled Web Portal for GROMACS Molecular Dynamics Simulations. , 2012, Journal of chemical theory and computation.
[98] Thomas Stützle,et al. Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..
[99] Hugo Gutiérrez-de-Terán,et al. Linear interaction energy: method and applications in drug design. , 2012, Methods in molecular biology.
[100] Victor Guallar,et al. Peripheral heme substituents control the hydrogen-atom abstraction chemistry in cytochromes P450 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[101] Jens Carlsson,et al. Improving the Accuracy of the Linear Interaction Energy Method for Solvation Free Energies. , 2007, Journal of chemical theory and computation.
[102] J L Kelsey,et al. Reproductive factors and breast cancer. , 1993, Epidemiologic reviews.
[103] K. Wähälä,et al. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: A molecular modelling study , 2009, Molecular and Cellular Endocrinology.